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The objective of the study was to measure antiretroviral exposures in four physiological compartments
during pregnancy, delivery, and postpartum. This prospective, open-label, longitudinal study collected paired
blood plasma (BP) and genital tract (GT) aspirates antepartum, at delivery, and up to 12 weeks postpartum.
Antiretroviral cord BP and amniotic fluid concentrations were also measured. Drug concentrations were
analyzed by validated high-performance liquid chromatography/UV and liquid chromatography/tandem mass
spectrometry methods, with secondary compartment concentrations presented as the percentage of BP. Four-
teen women taking lamivudine plus zidovudine and either lopinavir-ritonavir (n  7), nelfinavir (n  6), or
nevirapine (n  1) were enrolled; four also received tenofovir. GT penetration relative to BP was highest for
the nucleoside reverse transcriptase inhibitors compared to the protease inhibitors and nevirapine. Only
antepartum nelfinavir GT penetration was significantly higher than in the second trimester (geometric mean
ratio [GMR], 179.3) or third trimester (GMR, 41.9). Compared to nonpregnant historical controls, antepar-
tum GT penetration was significantly lower (P < 0.05) for zidovudine (GMR, 0.25) and lopinavir (GMR, 0.03);
postpartum lopinavir GT penetration continued to be significantly lower (GMR, 0.27). Cord BP exposures were
highest for lamivudine and tenofovir (>100%), with cord BP levels of the remaining drugs ranging from 49 to
86% of that of the respective BP level. Amniotic exposures for lamivudine, zidovudine, tenofovir, and nelfinavir
were >100%, nevirapine exposure was 53%, and lopinavir and ritonavir exposures were <6% that of BP. We
conclude that GT, cord BP, and amniotic fluid exposures vary within and between antiretroviral drug classes
and biologic sites. Measurement of antiretroviral exposure in maternal genital secretions, cord BP, and
amniotic fluid may be needed to identify signals of subtherapeutic or supratherapeutic drug exposure.
The widespread use of highly active antiretroviral (ARV)
therapy in human immunodeficiency virus (HIV)-infected
pregnant women and their infants has decreased mother-to-
child transmission of HIV to less than 2% in developed coun-
tries (3, 16). Recent data for HIV-infected pregnant women
suggest that plasma concentrations of protease inhibitors (PI)
decrease during the third trimester (43, 50). Similar pregnancy-
induced alterations in drug exposure have been observed for
other therapeutic classes (e.g., antiepileptics, antidepressants,
and antihypertensives) (19). These variations may be due to
increased hepatic blood flow, increased volume of distribution,
and/or alterations in drug-binding proteins (50, 55). Addition-
ally, increased hormone production during pregnancy may
cause induction of cytochrome P450 (CYP) enzyme activity
(e.g., CYP3A4) (25, 40). These influences, taken together, may
reduce concentrations of PIs and nonnucleoside reverse trans-
criptase inhibitors. Significant reductions in ARV concentra-
tions increase the risk of incomplete suppression of viral rep-
lication and subsequent development of resistance (49, 54).
Likewise, incomplete viral suppression may increase the risk of
perinatal transmission (2).
Quantifying drug exposure in body compartments with which
the infant has contact during pregnancy and delivery (genital
tract, cord blood plasma, and amniotic fluid) may assist in select-
ing optimal drug regimens. This open-label, prospective, longitu-
dinal, cohort study in HIV type 1 (HIV-1)-infected pregnant
women initiating or continuing highly active ARV therapy was
performed to measure the exposures of seven ARVs in four
physiologic compartments during pregnancy, delivery, and post-
partum.
(This research was previously presented in part at the 33rd
Scientific Meeting of the Infectious Diseases Society for Obstet-
rics and Gynecology, Monterey, CA, 3 to 5 August 2006, and as a
poster at the 46th Interscience Conference of Antimicrobial
Agents and Chemotherapy, San Francisco, CA, 26 to 28 Septem-
ber 2006 [62].)
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HIV-1-infected pregnant women were recruited from the Infectious Diseases
(ID) Clinic and the Obstetrics and Gynecology (OB/GYN) Clinic at the Univer-
sity of North Carolina at Chapel Hill (UNC) and enrolled in the study from
February 2004 to December 2005. Subjects were included if they were 18 years
of age, pregnant, had documented HIV-1 infection, and were planning to initiate
or were currently receiving ARV therapy. All ARVs were selected by the sub-
ject’s HIV health care provider. Subjects were excluded if they had active op-
portunistic or serious bacterial complications at the time of enrollment or had
past or present obstetrical complications, including multiple gestation, placentia
previa, eclampsia, confirmed birth defects, or chromosomal anomalies. The study
protocol was approved by the UNC Biomedical Institutional Review Board, and
all subjects provided written informed consent prior to any study procedure.
Subjects were eligible for enrollment after 10 weeks of gestation and com-
pleted at least monthly evaluations in conjunction with regularly scheduled
OB/GYN or ID appointments until 12 weeks postpartum. Study visits occurred
every 4 weeks from gestation weeks 10 through 34. After this time, samples were
collected weekly until delivery. Postpartum visits occurred at 2, 6, and 12 weeks.
At each study visit, subject weight, vital signs, and general health were assessed
and paired blood plasma, cervicovaginal fluid, and urine specimens were col-
lected. At delivery, blood plasma, cord blood plasma, and amniotic fluid (when
possible) were obtained. Morning doses were withheld until after blood and
genital tract sampling were completed. Adherence was assessed by a drug diary
card at each visit which documented ARV dose timing for the previous 3 days.
Direct questioning was utilized to assess adherence for the week prior to each
study visit. Outpatient study visits were conducted at the UNC Verne S. Caviness
General Clinical Research Center, ID clinic, or the OB/GYN clinic. Inpatient
delivery stays were at the UNC Women’s Hospital.
A separate daily drug dosing card was provided for documentation of ARV
adherence from week 37 of gestation to the time of delivery. All women deliv-
ering at UNC Hospitals received intravenous zidovudine (ZDV) as a 2-mg/kg of
body weight bolus over 1 h, administered at least 6 h prior to a scheduled elective
cesarean section or at the onset of labor for vaginal delivery. A continuous ZDV
1-mg/kg/h infusion was maintained until the umbilical cord was ligated (15).
Samples for ARV concentrations were obtained as follows: maternal blood on
presentation to labor and delivery; mixed umbilical venous/arterial cord blood at
delivery; maternal blood within 1 hour of cord blood collection. Amniotic fluid
was obtained from women who underwent cesarean delivery.
Cervicovaginal fluid samples for ARV concentration were self-collected by
direct aspiration of pooled fluid from the posterior fornix of the vagina using a
cervicovaginal fluid collection device (Rovumeter; Recipe Pharmaceuticals, Mu-
nich, Germany) except for those collected during speculum pelvic examination at
the baseline visit and week 35 or 36. Previous studies have demonstrated repro-
ducible pharmacokinetic results with this collection method (18, 34). The cervi-
covaginal fluid was transferred into a 1-ml preweighed cryovial containing 1 ml
0.01 mM ammonium acetate buffer and stored at 80°C until analysis. Cervico-
vaginal fluid volumes typically ranged from 0.1 to 0.4 ml per sample.
At study entry, during the second trimester (optional), and between 35 and 36
weeks of gestation, cervical fluid samples for HIV-1 RNA were collected by
pelvic exam using five Sno-strips (Akron, Abita Spring, LA) placed through the
cervical os into the distal endocervical canal. The strips were removed after
absorbed secretions reached past the shoulder (approximately 3 min). At all
other time points, five Sno-strips were touched to the cervicovaginal fluid col-
lection device and held in place until fluid was fully wicked. The strips were cut
at the shoulder (8 l of specimen/strip) over a cryovial containing 1 ml NASBA
buffer (bioMerieux, Inc., St. Louis, MO) and stored at 80°C until analysis.
All blood samples were collected in vacutainers (BD Diagnostics, Franklin
Lakes, NJ) containing 8.55 mg K3EDTA, kept on ice, and centrifuged at 2,600
rpm at 4°C for 15 min. The resulting plasma was aliquoted and stored at 80°C
until analysis.
To evaluate whether changes in ARV drug exposures were related to changes
in CYP3A activity, morning spot urine collections were obtained. Subjects col-
lected a first morning urine sample (30 ml) in a sterile urine container. This
sample was refrigerated until transport to the clinic in an insulated carrier.
CYP3A activity was estimated by measuring the urinary 6-hydroxycortisol/
cortisol ratio. Urine was mixed, aliquoted, and stored at 80°C until analysis.
Analytical methods. All analytical work for drug concentrations was per-
formed by the UNC Center for AIDS Research (CFAR) Clinical Pharmacology
and Analytical Chemistry Core, which participates in quarterly national and
international external ARV proficiency testing and for which 95% accuracy
and precision have been reported (17, 20). Drug concentrations in blood plasma,
cord blood plasma, and amniotic fluid were determined using validated high-
performance liquid chromatography (HPLC)/UV methods (45–47), and
HPLC/UV assay sensitivity was 25 ng/ml for nelfinavir (NFV), lopinavir (LPV),
and ritonavir (RTV) and 10 ng/ml for the remaining drugs. Drug concentrations
in cervicovaginal fluid were quantified using a validated HPLC/tandem mass
spectrometry (MS/MS) method (22). The HPLC/MS/MS assay sensitivity was 1
ng/ml for NFV and nevirapine (NVP), 5 ng/ml for tenofovir (TNF), 10 ng/ml for
ZDV and LPV, 40 ng/ml for RTV, and 50 ng/ml for lamivudine (3TC). ARV
extraction efficiency ranged from 80 to 99%, with excellent intra- and interday
precision (2.0 to 14.3%) and accuracy (88 to 113%).
HIV-1 RNA concentrations were measured by the UNC CFAR Virology
Core. Blood plasma samples were analyzed with the Roche Amplicor Monitor
test, version 1.5 (lower limit of quantitation [LLQ], 50 copies/ml). Genital tract
HIV-1 RNA was quantified using the Organon Teknika NucliSens test (LLQ,
400 copies/ml).
An LC/MS/MS system (Sciex-4000; Applied Biosystems) was used to quantify
urinary cortisol and 6-hydroxycortisol concentrations. Briefly, samples were
prepared by adding 25 l of 10 nM 6-methylprednisolone solution (internal
standard) and 100 l acetonitrile to 50 l urine. Solutions were vortexed and
centrifuged, and the supernatants were evaporated to dryness under nitrogen.
The residues were reconstituted with HPLC water and injected into a column for
chromatographic separation of cortisol, 6-hydroxycortisol, and 6-methylpred-
nisolone. A gradient elution through a Zorbax SB C18 Aq column (150 by 3.0
mm; 3.5-m particle size) over 14 min separated the analytes. Detection was
performed using electrospray ionization in negative mode. The deprotonated
molecules as parent and most suitable daughter ions for MS/MS transition for
cortisol, 6-hydroxycortisol, and the internal standard were m/z 361.17 to 331.04,
m/z 377.2 to 347.0, and m/z 373.2 to 343.06, respectively. Standard curves were
linear over a range of 1.5 nM to 1,500 nM for cortisol and 15 nM to 1,500 nM for
6-hydroxycortisol. Intra- and interday precision levels were 20%, and accu-
racy was 80%.
Data analysis and statistical methods. With the exception of delivery, samples
were selected for analysis if they were obtained within 3 h of the end of each
drug’s dosing interval. For calculation purposes, HIV-1 RNA concentrations
below the LLQ were imputed as equal to the LLQ; ARV concentrations below
the LLQ were imputed as 1/2 the LLQ. The penetration of a drug into a
secondary compartment (genital tract, cord blood plasma, and amniotic fluid)
relative to blood plasma is represented as a ratio (genital tract/blood plasma,
cord blood plasma/blood plasma, and amniotic fluid/blood plasma) (18, 44).
Linear mixed modeling was used to evaluate changes in individual drug con-
centrations in blood plasma, genital tract, and genital tract/blood plasma ratios
during pregnancy (second and third trimesters) and postpartum, considering
compound symmetry covariance structure to account for within-subject variation.
Variability in drug concentrations is represented by the coefficient of variation.
Drug concentration comparisons by pregnancy periods are presented as geomet-
ric mean ratios, with a 98.3% confidence interval with Bonferroni correction for
multiple comparisons. Drug concentrations are presented as medians (and 25th
and 75th percentiles) unless otherwise noted. Multivariable analyses were per-
formed to evaluate predictors of HIV-1 RNA in blood for patients taking 3TC-
ZDV-NFV and 3TC–ZDV–LPV-RTV.
Previously described cohorts were used for comparison (18, 34, 57) and are
referred to as nonpregnant historical controls. These were 27 HIV-1-infected,
nonpregnant women enrolled in an observational, open-label prospective, phar-
macokinetic study that measured exposure to 11 ARVs (not including NFV) in
cervicovaginal fluid and blood plasma.
RESULTS
Subject demographics. The demographics of women (n 
14) enrolled into the study are shown in Table 1. Most were
enrolled during their second trimester. One subject withdrew
consent after delivery. Four subjects (29%) were taking ARVs
before becoming pregnant (median, 91 weeks [range, 22 to
108] prior to study entry), and 10 started their ARV regimen
during pregnancy (median, 18 weeks gestation [range, 12 to
36]). Most were on their first ARV regimen, with 13/14 (93%)
on PI-based regimens and 1/14 on NVP. Women on LPV-RTV
were taking the 133.3/33.3-mg soft-gel capsule formulation and
those on NFV were taking the 250-mg tablets. All were pre-
scribed nucleoside reverse transcriptase inhibitors (NRTIs),
including 3TC, ZDV, stavudine (d4T), enteric coated di-
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danosine (ddI EC), and tenofovir disoproxil fumarate (TDF).
Average 7-day self-reported adherence was 96% antepartum
and 86% postpartum.
HIV RNA concentrations in blood plasma and the genital
tract. HIV-1 RNA concentrations were determined in 103
blood plasma and 65 genital tract samples from 14 women. In
the four women starting ARVs prior to pregnancy, 23%, 40%,
and 75% of blood plasma samples had HIV-1 RNA levels of
50 copies/ml in the second trimester (n  13), third trimester
(n  15), and postpartum (n  8), respectively. At these same
sampling times, 43%, 20%, and 12% of blood plasma samples
had HIV-1 RNA levels of 400 copies/ml, respectively. How-
ever, 80% of the samples with detectable HIV-1 RNA were
from two women who required a change in their ARV regimen
during pregnancy. At 33 weeks, one subject was switched from
3TC-ZDV-NFV to 3TC–ZDV–TDF–LPV-RTV (at standard
doses) and had HIV-1 RNA levels of 50 copies/ml at 36
weeks. The second subject (who had a history of anemia) was
switched from d4T–3TC–LPV-RTV to TDF–3TC–LPV-RTV
at 21 weeks. Of 21 genital tract samples available for HIV-1
RNA quantitation, only 1 sample (4.8%) had a detectable
HIV-1 RNA level of 400 copies/ml.
In the 10 women starting ARV therapy during pregnancy,
39%, 49%, and 33% of blood plasma samples had HIV-1 RNA
levels of 50 copies/ml in the second trimester (n  18), third
trimester (n  37), and postpartum (n  12), respectively.
Seven of the 10 women achieved plasma HIV-1 RNA levels of
50 copies/ml by a median of 7 weeks (range, 4 to 13) after
initiation of therapy. At these same sampling times, 94%, 92%,
and 50% of genital tract samples had HIV-1 RNA levels of
400 copies/ml, respectively. Three of the 10 women had de-
tectable genital tract HIV-1 RNA at study entry, and 2
achieved undetectable genital tract HIV-1 RNA (400 copies/
ml) by 4 weeks (the third subject was lost to follow-up). No
significant differences in HIV-1 RNA were observed in either
blood plasma or genital tract by pregnancy period, and no
significant correlations with ARV concentrations were noted.
Antiretroviral concentrations in the genital tract. Drug con-
centrations were measured in 80 blood plasma and 46 genital
tract samples. Individual paired blood plasma and genital tract
concentrations for each drug are shown in Fig. 1a to f. Similar
to nonpregnant historical controls (18, 34, 57), ARV concen-
trations were more variable in the genital tract than blood
plasma: intra- and intersubject variabilities in the genital tract
ranged from 47 to 223% and 92 to 317%, respectively, while
intra- and intersubject variabilities in blood plasma ranged
from 3 to 176% and 14 to 447%, respectively. No differences in
variability were seen between antepartum and postpartum
samples.
Overall, genital tract penetration in pregnant women, rela-
tive to drug levels in blood plasma, was highest for the NRTIs
compared to the PIs and NVP. No statistically significant dif-
ferences in genital tract penetration were observed for any of
the ARVs between the second and third trimesters. During
pregnancy, only NFV genital tract penetration was significantly
higher postpartum compared to the second trimester (geomet-
ric mean ratio [GMR], 179.3; 98.3% confidence interval [CI],
38.6 to 903.6) and third trimester (GMR, 41.9; 98.3% CI, 3.7 to
470.6), respectively. Compared to nonpregnant historical con-
trols, antepartum genital tract penetration was significantly
lower (P  0.05) for ZDV (GMR, 0.25; 98% CI, 0.08 to 0.75)
and LPV (GMR, 0.03; 98% CI, 0.01 to 0.17). Postpartum LPV
genital tract penetration continued to be significantly lower
than in nonpregnant historical controls (GMR, 0.27; 98.3% CI,
0.08 to 0.91).
Antiretroviral concentrations in cord blood plasma. Four
(29%) subjects delivered at an outside hospital and delivery
samples were not obtained. Of the remaining 10 women, 8
delivered by cesarean section and 2 by vaginal delivery (10 cord
blood plasma samples were collected). Paired maternal and
cord blood plasma samples were obtained a median of 15.5
hours (range, 11.7 to 54.7) after the last dose. Table 2
summarizes drug concentrations in maternal blood plasma,
cord blood plasma, and amniotic fluid and corresponding
TABLE 1. Demographics and antiretroviral regimen components
for the 14 study women
Characteristic Value
At enrollment
Median (IQR)a age (yrs) .................................27.5 (22.0, 30.0)
Median (IQR) gestational age (wks) .............19.5 (13.5, 27.5)
Median (IQR) weight (kg) ..............................83.8 (68.9, 107.3)
Median (IQR) body mass index (kg/m2) .......31.4 (25.4, 41.2)
Median (range) HIV-1 RNA
(copies/ml) in:
Blood plasma.................................................1,360 (85, 195,000)
Genital tract...................................................400 (400, 400,000)
Median (range) CD4 T-cell count
(cells/mm3) .....................................................456 (230, 1,006)
Race or ethnicity
No. (%) African-American..........................9 (64)
No. (%) Caucasian .......................................3 (21)
No. (%) Hispanic..........................................2 (14)
No. (%) with indicated ARV experience
First regimen .................................................10 (71)
Second regimen.............................................2 (14)
Multiple regimens .........................................2 (14)
No. (%) receiving indicated NRTI
3TC, 150 mg twice daily...................................14 (100)
ZDV, 300 mg twice daily .................................13 (93)
TDF, 300 mg once daily ..................................3 (21)
d4T, 40 mg twice daily .....................................1 (7)
ddI EC, 400 mg once daily ..............................1 (7)
No. (%) receiving indicated NNRTI and PI
NVP, 200 mg twice daily..................................1 (7)
LPV-RTV, 400 and 100 mg twice daily .........7 (50)
NFV, 1,250 mg twice daily ..............................6 (43)
Median (range) HIV-1 RNA (copies/ml)b
in blood plasma during:
Second trimester (n  31)...............................205 (50, 11,300)
Third trimester (n  52)..................................67 (50, 7,755)
Postpartum (n  20) ........................................50 (50, 13,181)
Median (range) HIV-1 RNA (copies/ml)b
in genital tract
Second trimester (n  24)...............................400 (400, 33,000)
Third trimester (n  33)..................................400 (400, 52,000)
Postpartum (n  8) ..........................................400 (400, 26,000)
a IQR, interquartile range.
b Data exclude enrollment values.
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FIG. 1. Individual blood plasma (BP) and genital tract (GT) drug concentrations by pregnancy period (17, 33, 56). N, number of paired BP and
GT samples by period (second trimester, third trimester, postpartum, and nonpregnant historical controls, respectively). For panel f, NFV
concentrations in nonpregnant historical controls were not available. GT/BP ratios show the median genital tract drug penetration as a fraction
of blood plasma drug concentration. IQR, interquartile range.
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ratios during delivery. NRTI concentrations in cord blood
plasma were similar to those in maternal blood plasma except
for TNF, for which cord blood plasma drug concentrations
were six times higher than maternal blood plasma. For the PIs
evaluated, median cord blood plasma drug concentrations
were 43 to 51% lower than drug concentrations in maternal
blood plasma. In the single subject receiving NVP, the cord
blood plasma drug concentration was 41% lower than in ma-
ternal blood plasma.
Antiretroviral concentrations in amniotic fluid. Although
eight women underwent cesarean section, two subjects had
amniotic membrane rupture prior to the procedure. Therefore,
six amniotic fluid samples were collected a median of 15.5
hours (range, 13.2 to 53.8) after the last ARV dose. In amniotic
fluid, NRTI concentrations were higher than in maternal blood
plasma. 3TC and ZDV amniotic fluid concentrations were
14-fold and 4-fold higher than in maternal blood plasma,
respectively. TNF amniotic fluid concentration (n  1) was 158
times higher than in maternal blood plasma. NVP amniotic
fluid concentration (n  1) was 47% lower than in maternal
blood plasma. Median amniotic fluid concentrations for RTV
and LPV were 96% lower than in maternal blood plasma. The
NFV concentration in amniotic fluid (n  1) was similar to that
in maternal blood plasma.
6-Hydroxycortisol and cortisol concentrations in urine.
Urine samples were analyzed for 6-hydroxycortisol and cor-
tisol concentrations (n  29, 43, and 16 in the second and third
trimesters and postpartum, respectively). Median (range) uri-
nary 6-hydroxycortisol/cortisol ratios were 3.7 (0.7 to 14.9) in
the second trimester, 5.4 (0.6 to 14.1) in the third trimester,
and 9.0 (0 to 16.0) postpartum (P  0.0001). Given that urinary
cortisol ratios are usually 5.0 (13, 61), this suggests continued
CYP3A induction throughout pregnancy and postpartum, de-
spite the majority of subjects taking antiretrovirals that inhibit
CYP3A activity (LPV-RTV and NFV). Across the phases of
pregnancy, intrasubject variability in the ratios was 20 to 48%
and intersubject variability was 40 to 72%. No correlations
were noted between this ratio and antiretroviral drug exposure
in any matrix.
DISCUSSION
Previous studies using intensive pharmacokinetic sampling
of ARVs in pregnancy have noted significantly decreased third
trimester systemic exposure to NRTIs (ZDV and TNF) (8, 59)
and PIs (LPV and NFV) (7, 43, 50, 55, 56) compared to
postpartum levels. Significant decreases in the area under the
concentration-time curve from 0 h to time 	 (time between
dosing intervals) have been demonstrated for ZDV (59), TNF
(8), LPV (50), and NFV (7, 43, 56), while decreased trough
concentrations have been noted for TNF (8), LPV (50), and
NFV (55, 56). ARV blood plasma concentrations observed in
the present study were similar to those described in previous
reports (8, 23, 36, 38, 50, 56, 59).
Compared to nonpregnant historical controls, decreased geni-
tal tract drug concentrations and genital tract/blood plasma ratios
were observed for ZDV and LPV in the antepartum period.
These decreases extended to the postpartum period for LPV
(18). The disproportionate decrease in genital tract exposure
compared to systemic exposure may suggest that pregnancy-
related alterations in ARV concentrations occur in compart-
ments other than blood plasma. The mechanism driving these
alterations has not been fully elucidated. Drug penetration into
peripheral sites is strongly related to protein-binding capacity,
among other physicochemical characteristics. However, hor-
monal fluctuations and other maternal physiological changes
associated with pregnancy also influence drug transport pro-
tein or metabolizing enzyme activities (14). Whatever the
mechanism, significantly decreased ARV concentrations in the
pregnant female genital tract require some consideration.
It has been suggested that approximately 80% of HIV-1
vertical transmission occurs between 36 weeks of gestation and
delivery in women not receiving antiretroviral therapy (26).
HIV genital tract shedding has been seen in patients on ARV.
Therefore, even lower exposure in the genital tract during
pregnancy may result in increased risk of the mother shedding
and transmitting HIV to the baby (1, 21). Fortunately, no
infants in this study became infected with HIV despite these
decreased ARV concentrations in the genital tract. However,
our sample size was small; much larger studies will be needed
to detect the clinical impact of these alterations.
Cord blood plasma ARV concentrations in this study were
similar to previous reports, except for TNF (5, 6, 8, 10, 11,
30–32, 35, 36, 38, 48, 50, 55). Data suggest that TNF may cross
the placenta by passive diffusion (31), although both TDF (the
tenofovir prodrug) and TNF are substrates for various efflux
transporters expressed in the human placenta which regulate
drug transfer (24, 42, 52, 60). In the three subjects evaluated,
all had cord blood plasma drug concentrations three- to sev-
enfold higher than blood plasma drug concentrations. Previous
TABLE 2. Maternal blood plasma, cord blood plasma, and amniotic fluid drug concentrations during delivery
ARV No. of samplesa
Median drug concn (ng/ml) (IQR) in: Median ratio (IQR) of drug concentrations
Maternal blood plasma Cord blood plasma Amniotic fluid Cord blood/blood plasma Amniotic fluid/bloodplasma
Lamivudine 10 (2), 10 (2), 6 (0) 271 (32, 383) 216 (42, 366) 931 (422, 1,009) 1.00 (0.91, 1.18) 14.2 (10.4, 23.0)
Zidovudine 10 (0), 10 (0), 6 (0) 557 (326, 915) 605 (344, 779) 2,249 (1,413, 2,107) 0.86 (0.72, 1.05) 4.2 (3.2, 20.5)
Tenofovir 3 (3), 3 (0), 1 (0) 5 (5, 5) 30 (18, 36) 791 6.0 (3.5, 7.2) 158.2b
Lopinavir 6 (2), 6 (2), 3 (1) 3,451 (786, 4,480) 80 (24, 2,381) 60 (43, 197) 0.57 (0.05, 1.00) 0.06 (0.04, 1.0)
Ritonavir 6 (2), 6 (2), 3 (3) 256 (73, 353) 20 (13, 38) 12 (6, 12) 0.55 (0.09, 1.00) 0.02 (0.01, 0.04)
Nelfinavir 3 (1), 3 (1), 1 (1) 65 (39, 543) 25 (19, 262) 12 0.49 (0.44, 0.74) 1.00b
Nevirapine 1 (0), 1 (0), 1 (0) 2,595 1,538 1,385 0.59b 0.53b
a Values are the number of maternal blood plasma, cord blood plasma, and amniotic fluid samples (and number of samples below limit of quantification), respectively.
b Presented as the individual ratio.
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reports have not shown this level of exposure for either single
dosing (range, 0.35 to 1.01) or multiple dosing (range, 0.35 to
1.7) (8, 31, 48). Variations in sample timing may play a role in
the differential results seen. For the single-dose study, sam-
pling was performed closer to the time of the maximum drug
concentration in serum (median sampling time, 5.6 h postdose
[range, 2 to 19.5]). Sample timing was not reported for multi-
ple-dose studies. Sampling for the three maternal cord blood
plasma pairs in this study occurred later in the dosing interval
(closer to the time of the minimum serum drug concentration,
12 to 25 h after dosing).
Limited amniotic fluid samples were available. However, for
drugs for which at least three paired samples were collected,
amniotic fluid concentrations of 3TC and ZDV were up to
14-fold higher than blood plasma drug concentrations and
similar to previously published data (10, 11, 30). Although
previous investigations failed to do so (11), we were able to
detect LPV concentrations in amniotic fluid by using a more
sensitive assay. Median LPV concentrations in amniotic fluid
were 4% those in maternal blood plasma. As HIV-1 RNA was
not measured in amniotic fluid or cord blood, we cannot com-
ment on the antiviral activities in these compartments. How-
ever, the measured concentrations for LPV were above the
50% inhibitory concentration for wild-type HIV-1 (41).
Previous reports have proposed the use of the endogenous
urinary 6-hydroxycortisol/cortisol ratio to demonstrate
CYP3A induction during pregnancy (25, 51, 53). In our study,
13 women were taking antiretrovirals which inhibit CYP3A
activity, and 1 was taking an antiretroviral which induces
CYP3A activity. Despite this, 6-hydroxycortisol/cortisol ratios
from morning spot urine were similar to previous reports in
healthy subjects (13, 61) and, unexpectedly, were highest post-
partum. The inter- and intraindividual variabilities in our pa-
tients were similar to previous reports (12, 25). Both the high
intrasubject variability (up to 50%) and the lack of correlation
with drug exposure and postpartum changes in CYP3A suggest
limited clinical utility for urinary 6-hydroxycortisol/cortisol
ratios as a marker of CYP3A induction in HIV-infected preg-
nant women.
Finally, reported adherence in our study decreased from
approximately 96% antepartum to 86% postpartum. This is
consistent with recent data showing that perfect adherence (no
self-reported missed doses) rates decreased significantly from
75% antepartum to 65% postpartum (P  0.01) (4). Since
self-reported adherence tends to be higher than more objective
measures (e.g., MEMS TrackCaps and pill counts), our post-
partum adherence rate of 86% is likely an overestimate (9, 27,
28, 33). Despite adherence levels that may have been adequate
for viral suppression (27, 29, 37), overall rates of women who
had HIV RNA-1 levels of 50 copies/ml in blood plasma at
each time point were relatively low (mean, 40%). This was
likely due to the heterogeneity of treatment initiation and
baseline HIV RNA concentrations: most women began ther-
apy during the study period. In the women who initiated ther-
apy during pregnancy, 70% achieved plasma HIV-1 RNA lev-
els of 50 copies/ml by a median of 7 weeks (range, 4 to 13)
after therapy initiation, consistent with findings in clinical trials
(37, 58).
The exploratory nature of the study allowed pregnant
women to be enrolled regardless of ARV regimen. Due to
logistical difficulties in collecting timed samples in this popu-
lation, only samples collected within 3 h of the end of each
drug’s dosing interval were included in the analysis. Particu-
larly for drugs with short half-lives, this could have contributed
to increased intra- and interindividual variabilities in drug ex-
posures. However, even in nonpregnant, highly adherent, vi-
rologically suppressed patients, intraindividual variability in
blood plasma ARV concentrations was high (ranging from 24
to 92%) and may have been due to factors beyond timing of
sample collection (39).
In summary, measuring ARV penetration into the genital
tract, cord blood plasma, and amniotic fluid may be needed to
identify signals of subtherapeutic or supratherapeutic drug ex-
posure. Our data are important in assisting the effort to un-
derstand the rate and extent of ARV exposure in secondary
body compartments so that ARV regimens in pregnancy can
be optimized for maximum efficacy and minimal toxicity.
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